Omalizumab Treatment in Brittle Asthma

Postepy Dermatologii I Alergologii - Poland
doi 10.5114/pdia.2014.40658
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Termedia Sp. z.o.o.

Related search

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Lengthening Omalizumab Dosing Interval in Treatment of Moderate to Severe Persistent Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Loss of Asthma Control After Cessation of Omalizumab Treatment: Real Life Data

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2014English

Omalizumab in the Treatment of Severe Allergic (IgE-mediated) Asthma: An Update on Recent Developments

Clinical and Translational Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2013English

Brittle Asthma: Fiend or Phantom?

Thorax
PulmonaryRespiratory Medicine
1998English

Omalizumab in Patients With Severe Asthma and Persistent Sputum Eosinophilia

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Effects of Omalizumab on Blood Eosinophil Numbers in Patients With Allergic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Greater Treatment Benefit With Omalizumab in Children With Increased Asthma Severity: Exploratory Analyses From the Inner-City Anti-IgE Therapy for Asthma (ICATA) Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy